Targeting the BH3 domain mediated protein-protein interaction of Bcl-Xl through virtual screening

Journal of Chemical Information and Modeling

Volumn 50, Issue 5, 2010, Pages 906-923

  Mukherjee, Prasenjit ^a,b   Desai, Prashant ^a,c   Zhou, Yu Dong ^a   Avery, Mitchell ^a  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CULTURE; CELL DEATH; MACHINERY;

ANTI-CANCER THERAPIES; BCL-2 PROTEIN FAMILIES; BIOLOGICAL EVALUATION; INNOVATIVE STRUCTURES; PROGRAMMED CELL DEATHS; PROTEIN-PROTEIN INTERACTIONS; STRUCTURE ACTIVITY RELATIONSHIPS; VIRTUAL SCREENING STRATEGIES;

PROTEINS;

ANTINEOPLASTIC AGENT; LIGAND; PROTEIN BCL X;

ARTICLE; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; HUMAN; METABOLISM; NEOPLASM; PROTEIN TERTIARY STRUCTURE; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; BCL-X PROTEIN; BINDING SITES; HUMANS; LIGANDS; MODELS, MOLECULAR; NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77952788585     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci1000373     Document Type: Article

References (89)

1. Fulda, S.; Debatin, K. M. Modulation of apoptosis signaling for cancer therapy Arch. Immunol. Ther. Exp. 2006, 54 (3) 173-175
2. Thompson, C. B. Apoptosis in the pathogenesis and treatment of disease Science 1995, 267 (5203) 1456-1462
3. Hanahan, D.; Weinberg, R. A. The hallmarks of cancer Cell 2000, 100 (1) 57-70
4. Danial, N. N.; Korsmeyer, S. J. Cell death: critical control points Cell 2004, 116 (2) 205-219
5. Nicholson, D. W. From bench to clinic with apoptosis-based therapeutic agents Nature 2000, 407 (6805) 810-816
6. Kakehi, Y.; Zeng, Y. Receptors of TRAIL as the target of apoptosis-inducing therapy for genitourinary cancers New Perspect. Cancer Res. Ther. 2005, 377-391
7. McConkey, D. J. Resistance to apoptosis in cancer therapy Death Recept. Cancer Ther. 2005, 43-64
8. Bremer, E.; van Dam, G.; Kroesen, B. J.; de Leij, L.; Helfrich, W. Targeted induction of apoptosis for cancer therapy: current progress and prospects Trends Mol. Med. 2006, 12 (8) 382-393
9. Meng, X. W.; Lee, S. H.; Kaufmann, S. H. Apoptosis in the treatment of cancer: a promise kept Curr. Opin. Cell Biol. 2006, 18 (6) 668-676
10. Walters, W. P.; Namchuk, M. Designing screens: how to make your hits a hit Nat. Rev. Drug. Discovery 2003, 2 (4) 259-266
11. Secchiero, P.; Vaccarezza, M.; Gonelli, A.; Zauli, G. TNF-related apoptosis-inducing ligand (TRAIL): a potential candidate for combined treatment of hematological malignancies Curr. Pharm. Des. 2004, 10 (29) 3673-3681
12. Merino, D.; Lalaoui, N.; Morizot, A.; Solary, E.; Micheau, O. TRAIL in cancer therapy: present and future challenges Expert Opin. Ther. Targets 2007, 11 (10) 1299-1314
13. Johnstone, R. W.; Frew, A. J.; Smyth, M. J. The TRAIL apoptotic pathway in cancer onset, progression and therapy Nat. Rev. Cancer 2008, 8 (10) 782-798
14. Kirkin, V.; Joos, S.; Zornig, M. The role of Bcl-2 family members in tumorigenesis Biochim. Biophys. Acta 2004, 1644 (2-3) 229-249
15. Baell, J. B.; Huang, D. C. Prospects for targeting the Bcl-2 family of proteins to develop novel cytotoxic drugs Biochem. Pharmacol. 2002, 64 (5-6) 851-863
16. Deveraux, Q. L.; Takahashi, R.; Salvesen, G. S.; Reed, J. C. X-linked IAP is a direct inhibitor of cell-death proteases Nature 1997, 388 (6639) 300-304
17. Du, C.; Fang, M.; Li, Y.; Li, L.; Wang, X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition Cell 2000, 102 (1) 33-42
18. Verhagen, A. M.; Ekert, P. G.; Pakusch, M.; Silke, J.; Connolly, L. M.; Reid, G. E.; Moritz, R. L.; Simpson, R. J.; Vaux, D. L.; Identification of, DIABLO a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins Cell 2000, 102 (1) 43-53
19. Li, L.; Thomas, R. M.; Suzuki, H.; De Brabander, J. K.; Wang, X.; Harran, P. G. A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death Science 2004, 305 (5689) 1471-1474
20. Cossu, F.; Milani, M.; Mastrangelo, E.; Vachette, P.; Servida, F.; Lecis, D.; Canevari, G.; Delia, D.; Drago, C.; Rizzo, V.; Manzoni, L.; Seneci, P.; Scolastico, C.; Bolognesi, M. Structural basis for bivalent smac-mimetics recognition in the IAP protein family J. Mol. Biol. 2009, 392 (3) 630-644
21. Chen, D. J.; Huerta, S. Smac mimetics as new cancer therapeutics Anti-Cancer Drugs 2009, 20 (8) 646-658
22. Chene, P. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy Nat. Rev. Cancer 2003, 3 (2) 102-109
23. Vousden, K. H. Outcomes of p53 activation - spoilt for choice J. Cell Sci. 2006, 119 (Pt 24) 5015-5020
24. Vazquez, A.; Bond, E. E.; Levine, A. J.; Bond, G. L. The genetics of the p53 pathway, apoptosis and cancer therapy Nat. Rev. Drug. Discovery 2008, 7 (12) 979-987
25. Rayburn, E. R.; Ezell, S. J.; Zhang, R. Recent advances in validating MDM2 as a cancer target Anti-Cancer Agents Med. Chem. 2009, 9 (8) 882-903
26. Yu, S.; Qin, D.; Shangary, S.; Chen, J.; Wang, G.; Ding, K.; McEachern, D.; Qiu, S.; Nikolovska-Coleska, Z.; Miller, R.; Kang, S.; Yang, D.; Wang, S. Potent and Orally Active Small-Molecule Inhibitors of the MDM2-p53 Interaction J. Med. Chem. 2009
27. Oksanen, E.; Ahonen, A. K.; Tuominen, H.; Tuominen, V.; Lahti, R.; Goldman, A.; Heikinheimo, P. A complete structural description of the catalytic cycle of yeast pyrophosphatase Biochemistry 2007, 46 (5) 1228-1239
28. Yin, H.; Hamilton, A. D. Strategies for targeting protein-protein interactions with synthetic agents Angew. Chem., Int. Ed. Engl. 2005, 44 (27) 4130-4163
29. Toogood, P. L. Inhibition of protein-protein association by small molecules: approaches and progress J. Med. Chem. 2002, 45 (8) 1543-1558
30. Chene, P. Drugs targeting protein-protein interactions ChemMedChem 2006, 1 (4) 400-411
31. Fletcher, S.; Hamilton, A. D. Protein-protein interaction inhibitors: small molecules from screening techniques Curr. Top. Med. Chem. 2007, 7 (10) 922-927
32. DeLano, W. L. Unraveling hot spots in binding interfaces: progress and challenges Curr. Opin. Struct. Biol. 2002, 12 (1) 14-20
33. Chakrabarti, P.; Janin, J. Dissecting protein-protein recognition sites Proteins 2002, 47 (3) 334-343
34. Petros, A. M.; Olejniczak, E. T.; Fesik, S. W. Structural biology of the Bcl-2 family of proteins Biochim. Biophys. Acta 2004, 1644 (2-3) 83-94
35. Mikhailov, V.; Mikhailova, M.; Pulkrabek, D. J.; Dong, Z.; Venkatachalam, M. A.; Saikumar, P. Bcl-2 prevents Bax oligomerization in the mitochondrial outer membrane J. Biol. Chem. 2001, 276 (21) 18361-18374
36. Dlugosz, P. J.; Billen, L. P.; Annis, M. G.; Zhu, W.; Zhang, Z.; Lin, J.; Leber, B.; Andrews, D. W. Bcl-2 changes conformation to inhibit Bax oligomerization EMBO J. 2006, 25 (11) 2287-2296
37. Yano, M.; Terada, K.; Gotoh, T.; Mori, M. In vitro analysis of Bcl-2 proteins in mitochondria and endoplasmic reticulum: similarities in antiapoptotic functions and differences in regulation Exp. Cell Res. 2007, 313 (17) 3767-3778
38. Mikhailov, V.; Mikhailova, M.; Degenhardt, K.; Venkatachalam, M. A.; White, E.; Saikumar, P. Association of Bax and Bak homo-oligomers in mitochondria. Bax requirement for Bak reorganization and cytochrome c release J. Biol. Chem. 2003, 278 (7) 5367-5376
39. An, J.; Chen, Y.; Huang, Z. Critical upstream signals of cytochrome C release induced by a novel Bcl-2 inhibitor J. Biol. Chem. 2004, 279 (18) 19133-19140
40. Degenhardt, K.; Sundararajan, R.; Lindsten, T.; Thompson, C.; White, E. Bax and Bak independently promote cytochrome C release from mitochondria J. Biol. Chem. 2002, 277 (16) 14127-14134
41. Ruvkun, G. Molecular biology. Glimpses of a tiny RNA world Science 2001, 294 (5543) 797-799
42. Mohammad, R.; Giri, A.; Goustin, A. S. Small-molecule inhibitors of Bcl-2 family proteins as therapeutic agents in cancer Recent Pat. Anti-Cancer Drug Discovery 2008, 3 (1) 20-30
43. Amundson, S. A.; Myers, T. G.; Scudiero, D.; Kitada, S.; Reed, J. C.; Fornace, A. J., Jr. An informatics approach identifying markers of chemosensitivity in human cancer cell lines Cancer Res. 2000, 60 (21) 6101-6110
44. Reed, J. C. Promise and problems of Bcl-2 antisense therapy J. Natl. Cancer Inst. 1997, 89 (14) 988-990
45. Letai, A.; Sorcinelli, M. D.; Beard, C.; Korsmeyer, S. J. Antiapoptotic BCL-2 is required for maintenance of a model leukemia Cancer Cell 2004, 6 (3) 241-249
46. Klasa, R. J.; Gillum, A. M.; Klem, R. E.; Frankel, S. R. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment Antisense Nucleic Acid Drug Dev. 2002, 12 (3) 193-213
47. Minko, T.; Dharap, S. S.; Fabbricatore, A. T. Enhancing the efficacy of chemotherapeutic drugs by the suppression of antiapoptotic cellular defense Cancer Detect. Prev. 2003, 27 (3) 193-202
48. Chan, S. L.; Lee, M. C.; Tan, K. O.; Yang, L. K.; Lee, A. S.; Flotow, H.; Fu, N. Y.; Butler, M. S.; Soejarto, D. D.; Buss, A. D.; Yu, V. C. Identification of chelerythrine as an inhibitor of BclXL function J. Biol. Chem. 2003, 278 (23) 20453-20456
49. Degterev, A.; Lugovskoy, A.; Cardone, M.; Mulley, B.; Wagner, G.; Mitchison, T.; Yuan, J. Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL Nat. Cell Biol. 2001, 3 (2) 173-182
50. Rega, M. F.; Leone, M.; Jung, D.; Cotton, N. J.; Stebbins, J. L.; Pellecchia, M. Structure-based discovery of a new class of Bcl-xL antagonists Bioorg. Chem. 2007, 35 (4) 344-353
51. Wang, J. L.; Liu, D.; Zhang, Z. J.; Shan, S.; Han, X.; Srinivasula, S. M.; Croce, C. M.; Alnemri, E. S.; Huang, Z. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells Proc. Natl. Acad. Sci. U.S.A. 2000, 97 (13) 7124-7129
52. Kitada, S.; Leone, M.; Sareth, S.; Zhai, D.; Reed, J. C.; Pellecchia, M. Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins J. Med. Chem. 2003, 46 (20) 4259-4264
53. Petros, A. M.; Dinges, J.; Augeri, D. J.; Baumeister, S. A.; Betebenner, D. A.; Bures, M. G.; Elmore, S. W.; Hajduk, P. J.; Joseph, M. K.; Landis, S. K.; Nettesheim, D. G.; Rosenberg, S. H.; Shen, W.; Thomas, S.; Wang, X.; Zanze, I.; Zhang, H.; Fesik, S. W. Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis J. Med. Chem. 2006, 49 (2) 656-663
54. Tzung, S. P.; Kim, K. M.; Basanez, G.; Giedt, C. D.; Simon, J.; Zimmerberg, J.; Zhang, K. Y.; Hockenbery, D. M. Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3 Nat. Cell Biol. 2001, 3 (2) 183-191
55. Leone, M.; Zhai, D.; Sareth, S.; Kitada, S.; Reed, J. C.; Pellecchia, M. Cancer prevention by tea polyphenols is linked to their direct inhibition of antiapoptotic Bcl-2-family proteins Cancer Res. 2003, 63 (23) 8118-8121
56. Real, P. J.; Cao, Y.; Wang, R.; Nikolovska-Coleska, Z.; Sanz-Ortiz, J.; Wang, S.; Fernandez-Luna, J. L. Breast cancer cells can evade apoptosis-mediated selective killing by a novel small molecule inhibitor of Bcl-2 Cancer Res. 2004, 64 (21) 7947-7953
57. Wang, G.; Nikolovska-Coleska, Z.; Yang, C. Y.; Wang, R.; Tang, G.; Guo, J.; Shangary, S.; Qiu, S.; Gao, W.; Yang, D.; Meagher, J.; Stuckey, J.; Krajewski, K.; Jiang, S.; Roller, P. P.; Abaan, H. O.; Tomita, Y.; Wang, S. Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins J. Med. Chem. 2006, 49 (21) 6139-6142
58. Wang, Y. Obatoclax Mesylate Drugs Future 2007, 32 (3) 228-233
59. Lugovskoy, A. A.; Degterev, A. I.; Fahmy, A. F.; Zhou, P.; Gross, J. D.; Yuan, J.; Wagner, G. A novel approach for characterizing protein ligand complexes: molecular basis for specificity of small-molecule Bcl-2 inhibitors J. Am. Chem. Soc. 2002, 124 (7) 1234-1240
60. Bruncko, M.; Oost, T. K.; Belli, B. A.; Ding, H.; Joseph, M. K.; Kunzer, A.; Martineau, D.; McClellan, W. J.; Mitten, M.; Ng, S. C.; Nimmer, P. M.; Oltersdorf, T.; Park, C. M.; Petros, A. M.; Shoemaker, A. R.; Song, X.; Wang, X.; Wendt, M. D.; Zhang, H.; Fesik, S. W.; Rosenberg, S. H.; Elmore, S. W. Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL J. Med. Chem. 2007, 50 (4) 641-662
61. Oltersdorf, T.; Elmore, S. W.; Shoemaker, A. R.; Armstrong, R. C.; Augeri, D. J.; Belli, B. A.; Bruncko, M.; Deckwerth, T. L.; Dinges, J.; Hajduk, P. J.; Joseph, M. K.; Kitada, S.; Korsmeyer, S. J.; Kunzer, A. R.; Letai, A.; Li, C.; Mitten, M. J.; Nettesheim, D. G.; Ng, S.; Nimmer, P. M.; O'Connor, J. M.; Oleksijew, A.; Petros, A. M.; Reed, J. C.; Shen, W.; Tahir, S. K.; Thompson, C. B.; Tomaselli, K. J.; Wang, B.; Wendt, M. D.; Zhang, H.; Fesik, S. W.; Rosenberg, S. H. An inhibitor of Bcl-2 family proteins induces regression of solid tumours Nature 2005, 435 (7042) 677-681
62. Park, C. M.; Bruncko, M.; Adickes, J.; Bauch, J.; Ding, H.; Kunzer, A.; Marsh, K. C.; Nimmer, P.; Shoemaker, A. R.; Song, X.; Tahir, S. K.; Tse, C.; Wang, X.; Wendt, M. D.; Yang, X.; Zhang, H.; Fesik, S. W.; Rosenberg, S. H.; Elmore, S. W. Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins J. Med. Chem. 2008, 51 (21) 6902-6915
63. Posner, B. A. High-throughput screening-driven lead discovery: meeting the challenges of finding new therapeutics Curr. Opin. Drug Discovery Dev. 2005, 8 (4) 487-494
64. Fox, S.; Farr-Jones, S.; Sopchak, L.; Boggs, A.; Comley, J. High-throughput screening: searching for higher productivity J. Biomol. Screening 2004, 9 (4) 354-358
65. Uciechowska, U.; Schemies, J.; Neugebauer, R. C.; Huda, E. M.; Schmitt, M. L.; Meier, R.; Verdin, E.; Jung, M.; Sippl, W. Thiobarbiturates as sirtuin inhibitors: virtual screening, free-energy calculations, and biological testing ChemMedChem 2008, 3 (12) 1965-1976
66. Park, H.; Jung, S. K.; Jeong, D. G.; Ryu, S. E.; Kim, S. J. Discovery of VHR phosphatase inhibitors with micromolar activity based on structure-based virtual screening ChemMedChem 2008, 3 (6) 877-880
67. Larsen, S. B.; Omkvist, D. H.; Brodin, B.; Nielsen, C. U.; Steffansen, B.; Olsen, L.; Jorgensen, F. S. Discovery of ligands for the human intestinal Di-/Tripeptide transporter (hPEPT1) using a QSAR-assisted virtual screening strategy ChemMedChem 2009, 4 (9) 1439-1445
68. Heinke, R.; Spannhoff, A.; Meier, R.; Trojer, P.; Bauer, I.; Jung, M.; Sippl, W. Virtual screening and biological characterization of novel histone arginine methyltransferase PRMT1 inhibitors ChemMedChem 2009, 4 (1) 69-77
69. Wu, S.; Bottini, M.; Rickert, R. C.; Mustelin, T.; Tautz, L. In silico screening for PTPN22 inhibitors: active hits from an inactive phosphatase conformation ChemMedChem 2009, 4 (3) 440-444
70. Nikolovska-Coleska, Z.; Wang, R.; Fang, X.; Pan, H.; Tomita, Y.; Li, P.; Roller, P. P.; Krajewski, K.; Saito, N. G.; Stuckey, J. A.; Wang, S. Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization Anal. Biochem. 2004, 332 (2) 261-273
71. Fang, X.; Wang, R. The Ki Calculator; http://sw16.im.med.umich.edu/ software/calc-ki. Accessed March 15, 2010.
72. Sattler, M.; Liang, H.; Nettesheim, D.; Meadows, R. P.; Harlan, J. E.; Eberstadt, M.; Yoon, H. S.; Shuker, S. B.; Chang, B. S.; Minn, A. J.; Thompson, C. B.; Fesik, S. W. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis Science 1997, 275 (5302) 983-986
73. Desai, P. V.; Patny, A.; Sabnis, Y.; Tekwani, B.; Gut, J.; Rosenthal, P.; Srivastava, A.; Avery, M. Identification of novel parasitic cysteine protease inhibitors using virtual screening. 1. The ChemBridge database J. Med. Chem. 2004, 47 (26) 6609-6615
74. Desai, P. V.; Patny, A.; Gut, J.; Rosenthal, P. J.; Tekwani, B.; Srivastava, A.; Avery, M. Identification of novel parasitic cysteine protease inhibitors by use of virtual screening. 2. The available chemical directory J. Med. Chem. 2006, 49 (5) 1576-1584
75. Mukherjee, P.; Desai, P.; Ross, L.; White, E. L.; Avery, M. A. Structure-based virtual screening against SARS-3CL(pro) to identify novel non-peptidic hits Bioorg. Med. Chem. 2008, 16 (7) 4138-4149
76. Carlson, H. A. Protein flexibility and drug design: how to hit a moving target Curr. Opin. Chem. Biol. 2002, 6 (4) 447-452
77. Nakajima, N.; Higo, J.; Kidera, A.; Nakamura, H. Flexible docking of a ligand peptide to a receptor protein by multicanonical molecular dynamics simulation Chem. Phys. Lett. 1997, 278 (4,5,6) 297-301
78. Wasserman, Z. R.; Hodge, C. N. Fitting an inhibitor into the active site of thermolysin: a molecular dynamics case study Proteins 1996, 24 (2) 227-237
79. Di Nola, A.; Roccatano, D.; Berendsen, H. J. Molecular dynamics simulation of the docking of substrates to proteins Proteins 1994, 19 (3) 174-182
80. Mangoni, M.; Roccatano, D.; Di Nola, A. Docking of flexible ligands to flexible receptors in solution by molecular dynamics simulation Proteins 1999, 35 (2) 153-162
81. Sherman, W.; Day, T.; Jacobson, M. P.; Friesner, R. A.; Farid, R. Novel procedure for modeling ligand/receptor induced fit effects J. Med. Chem. 2006, 49 (2) 534-553
82. Carlson, H. A.; McCammon, J. A. Accommodating protein flexibility in computational drug design Mol. Pharmacol. 2000, 57 (2) 213-218
83. Jiang, F.; Kim, S. H. Soft docking": matching of molecular surface cubes J. Mol. Biol. 1991, 219 (1) 79-102
84. Knegtel, R. M.; Kuntz, I. D.; Oshiro, C. M. Molecular docking to ensembles of protein structures J. Mol. Biol. 1997, 266 (2) 424-440
85. Broughton, H. B. A method for including protein flexibility in protein-ligand docking: improving tools for database mining and virtual screening J. Mol. Graph. Model. 2000, 18 (3) 247-257 302-244
86. Osterberg, F.; Morris, G. M.; Sanner, M. F.; Olson, A. J.; Goodsell, D. S. Automated docking to multiple target structures: incorporation of protein mobility and structural water heterogeneity in AutoDock Proteins 2002, 46 (1) 34-40
87. Sherman, W.; Beard, H. S.; Farid, R. Use of an induced fit receptor structure in virtual screening Chem. Biol. Drug. Des. 2006, 67 (1) 83-84
88. Irwin, J. J.; Shoichet, B. K. ZINC - a free database of commercially available compounds for virtual screening J. Chem. Inf. Model. 2005, 45 (1) 177-182
89. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection Drug Discovery Today 2004, 9 (10) 430-431